Chemotherapy-Induced Amenorrhea in Patients With Breast Cancer With a BRCA1 or BRCA2 Mutation by Valentini, A et al.
Title Chemotherapy-Induced Amenorrhea in Patients With BreastCancer With a BRCA1 or BRCA2 Mutation
Author(s)
Valentini, A; Finch, A; Lubiski, J; Byrski, T; Ghadirian, P; Kim-
Sing, C; Lynch, HT; Ainsworth, PJ; Neuhausen, SL; Greenblatt,
E; Singer, C; Sun, P; Narod, SA; Kwong, A
Citation Journal of Clinical Oncology, 2013, v. 31, p. 3914-3919
Issued Date 2013
URL http://hdl.handle.net/10722/251821
Rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Chemotherapy-Induced Amenorrhea in Patients With
Breast Cancer With a BRCA1 or BRCA2Mutation
Adriana Valentini, Amy Finch, Jan Lubin´ski, Tomasz Byrski, Parviz Ghadirian, Charmaine Kim-Sing,
Henry T. Lynch, Peter J. Ainsworth, Susan L. Neuhausen, Ellen Greenblatt, Christian Singer, Ping Sun,
and Steven A. Narod
See accompanying article on page 3920
Adriana Valentini, Amy Finch, Ping Sun,
and Steven A. Narod, Women’s College
Research Institute; Ellen Greenblatt,
Centre for Fertility and Reproductive
Health, Mount Sinai Hospital, University
of Toronto, Toronto; Peter J. Ainsworth,
London Regional Cancer Program,
London, Ontario; Parviz Ghadirian,
Research Center of the University of
Montreal Hospital Centre, Montreal,
Quebec; Charmaine Kim-Sing, BC
Cancer Agency, Vancouver, British
Columbia, Canada; Henry T. Lynch,
Creighton University School of Medi-
cine, Omaha, NE; Susan L. Neuhausen,
Beckman Research Institute, City of
Hope, Duarte, CA; Jan Lubin´ski and
Tomasz Byrski, Hereditary Cancer
Center, Pomeranian Medical University,
Szczecin, Poland; and Christian Singer,
Comprehensive Cancer Center, Medical
University of Vienna, Vienna, Austria.
Published online ahead of print at
www.jco.org on August 26, 2013.
Written on behalf of the Hereditary
Breast Cancer Clinical Study Group.
Supported by the Canadian Breast
Cancer Research Alliance, the Canadian
Cancer Research Society Research
Initiative, Fonds de Recherche en Sante´
du Que´bec, and National Institutes of
Health Grant No. R01 CA74415.
Authors’ disclosures of potential con-
flicts of interest and author contribu-
tions are found at the end of this
article.
Corresponding author: Steven A. Narod,
MD, Women’s College Research Insti-
tute, 790 Bay St, Room 750, Toronto,
Ontario, Canada, M5G 1N8; e-mail:
steven.narod@wchospital.ca.
© 2013 by American Society of Clinical
Oncology
0732-183X/13/3131w-3914w/$20.00
DOI: 10.1200/JCO.2012.47.7893
A B S T R A C T
Purpose
To determine the likelihood of long-term amenorrhea after treatment with chemotherapy in
women with breast cancer who carry a BRCA1 or BRCA2 mutation.
Patients and Methods
We conducted a multicenter survey of 1,954 young women with a BRCA1 or BRCA2 mutation
who were treated for breast cancer. We included premenopausal women who were diagnosed
with invasive breast cancer between 26 and 47 years of age. We determined the age of onset of
amenorrhea after breast cancer for women who were and were not treated with chemotherapy,
alone or with tamoxifen. We considered chemotherapy-induced amenorrhea to have occurred
when the patient experienced  2 years of amenorrhea, commencing within 2 years of initiating
chemotherapy, with no resumption of menses.
Results
Of the 1,426 women who received chemotherapy, 35% experienced long-term amenorrhea. Of
the 528 women who did not receive chemotherapy, 5.3% developed long-term amenorrhea. The
probabilities of chemotherapy-induced amenorrhea were 7.2% for women diagnosed before age
30 years, 33% for women age 31 to 44 years, and 79% for women diagnosed after age 45 years
(P trend  .001). The probability of induced amenorrhea was higher for women who received
tamoxifen than for those who did not (52% v 29%; P  .001).
Conclusion
Age at treatment and use of tamoxifen are important predictors of chemotherapy-induced
amenorrhea in women who carry a BRCA1 or BRCA2 mutation. The risk of induced long-term
amenorrhea does not seem to be greater among mutation carriers than among women who do not
carry a mutation.
J Clin Oncol 31:3914-3919. © 2013 by American Society of Clinical Oncology
INTRODUCTION
In premenopausal women with breast cancer, the
benefits of treatmentmust be balancedby the effects
of treatment on fertility and quality of life. Among
the concernsof youngwomenwithbreast cancer are
premature menopause and infertility.1 Long-term
effects of treatment include osteoporosis, urogenital
dysfunction, cardiovascular disease, and cognitive
impairment.2 Many women with a BRCA1 or
BRCA2 mutation who are diagnosed with breast
cancer will seek the expertise of a fertility specialist,
who may recommend oocyte cryopreservation or
embryopreservation before treatment. This is based
on the expectation that a high proportion of these
womenwillberenderedamenorrheicbychemother-
apy and the hope that fertility can be preserved
through intervention. It has been proposed that
many BRCA mutation carriers who do not receive
chemotherapy will experience premature meno-
pause.3 It is important that patients and clinicians
have accurate information regarding the probabili-
ties of induced and natural menopause and the fac-
tors thatpredict amenorrhea in this high-risk group.
At birth, each ovary contains approximately
300,000 oocytes. The number of residual follicles
diminisheswith eachmenstrual cycle, and thenum-
ber of remaining follicles determines, in part, a
woman’s capability for fertility and is predictive of
time to menopause. At the age of 51 years, only
approximately 1,000 follicles remain.4,5 Women
treated for breast cancer are at risk of ovarian failure
after chemotherapy because of depletion of follicles.
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The incidence of chemotherapy-induced amenorrhea depends on the
patient’s age and the chemotherapy agent used.6
Ithasbeenproposed thatwomenwithaBRCA1mutationmaybe
more sensitive to the effects of chemotherapy on ovarian follicle de-
pletion thanwomenwithout amutation.3 This hypothesis is based on
a study of ovarian reserve of patients with breast cancer attending a
fertility clinic. Little is knownabout the risk of induced amenorrhea in
women with a BRCA1 or BRCA2 mutation. Our objective was to
estimate the probability of chemotherapy-induced amenorrhea for
premenopausal women with breast cancer and a BRCA1 or BRCA2
mutation. A secondary objective was to compare the age-specific
probabilities of experiencing chemotherapy-induced amenorrhea in
mutation carriers and noncarriers. Other members of the Hereditary
Breast Cancer Clinical Study Group are listed in the Appendix
(online only).
PATIENTS AND METHODS
Patientswere selected fromadatabase of 13,004BRCA1 andBRCA2mutation
carriers and 2,451 noncarriers. Study patients were identified at one of 62
participating centers in seven countries. These women sought testing for
BRCA1 andBRCA2mutationsbecauseof apersonal or familyhistoryof breast
or ovarian cancer. The institutional review boards of the host institutions
approved the study.All patientsprovidedwritten informedconsent.Mutation
detection was performed using a range of techniques, but all nucleotide se-
quenceswere confirmedbydirect sequencing ofDNA.Awomanwas enrolled
onto theBRCA carrier groupwhen themolecular analysis established that she
was a carrier of a deleteriousmutation inBRCA1 orBRCA2. All study patients
completed a baseline questionnaire. The questionnaire requested information
on family andpersonal histories of cancer, reproductive andmedical histories,
anddate andcauseofmenopause. Forwomenwithbreast cancer, information
was collectedon typesof therapyadministered, including chemotherapy (yes v
no), hormonal therapy, and ovarian ablation.We did not have details on type
of chemotherapy.
In our study, we includedmutation carriers from the parent study, who
were diagnosedwith invasive breast cancer between 26 and 47 years of age and
who were premenopausal at the time of diagnosis. The date of breast cancer
was considered the date of surgery. We considered the definition of induced
menopause as 2 years of amenorrhea commencing within 2 years of chem-
otherapy with no resumption of menses. We considered natural amenorrhea
to have occurred when the onset of amenorrhea was  2 years after breast
cancer treatment. For women who did not receive chemotherapy, we consid-
ered the onset of amenorrheawithin 2 years of the initiationof treatment to be
the relevant comparison period (in this sense, we used the term induced
amenorrhea throughout the text for comparison purposes, but given the
absence of chemotherapy, we recognize that these are likely to be examples of
naturalmenopause). As a consequence of this definition, we excluded carriers
if theyhadexperiencedmenopausebeforebreast cancerdiagnosis (n1,084),
if they were age 47 years at diagnosis (n 255), if they had undergone an
oophorectomy (bilateral or unilateral) or hysterectomywithin 2 years of diag-
nosis (n 213), or if the follow-up period did not extend to 2 years from the
onset of amenorrhea (n 1,202). We also excluded 102 carriers who devel-
oped ovarian cancer or a secondprimary breast cancerwithin 2 years of breast
cancer diagnosis, 338 carriers for whom genetic test results were of uncertain
clinical significance, and 554 carriers for whom information on key variables
was missing (ie, date of last menstrual period, date of breast cancer diagnosis,
or date of breast cancer treatment). In total, 1,954 BRCA carriers with breast
cancer were eligible.
We included 167 noncarrier womenwith breast cancer as a comparison
group. These were women who had been assessed for family history and had
undergone genetic testing for BRCA1 and BRCA2 mutations in the Narod
laboratory in Toronto between 1995 and 2012 and were found to be negative
for bothmutations. These women completed the same lifestyle/medical ques-
tionnaire as did the carrier women, and the exclusion criteria were identical.
Statistical Analysis
We estimated the proportion of women who experienced induced
amenorrhea as the number of women who experienced amenorrhea of 2
years duration after chemotherapy with no resumption ofmenses, divided by
the total number of women. Relevant subgroups included chemotherapy use
(yes v no), BRCA1 or BRCA2mutation, age at diagnosis (age of surgery), and
use of adjuvant hormonal therapy (tamoxifen). Between-group comparisons
were assessed for significance using the t test.
In a secondary analysis, carrier and noncarrier patients were compared
for menopause by comparing of the probabilities of induced amenorrhea by
age at treatment. The comparisonswere tested for statistical significance using
the Cochran-Mantel-Haenszel test for nonzero correlation.
RESULTS
Themedian age at diagnosis for carrierswas 37.3 years (range, 26 to 47
years; Table 1). All patients reported experiencingmenstrual cycles at
the time of breast cancer diagnosis. Of the 1,954 mutation carriers,
1,506 (77%) carried a BRCA1mutation, 436 (22%) carried a BRCA2
mutation, and 12 (0.6%) carried bothmutations. Of the 1,954 carrier
patients, 1,426 (73%) received chemotherapy. In total, 478 carrier
patients received tamoxifen, of whom 410 received both tamoxifen
and chemotherapy (86%).
Of the 1,426 carriers who received chemotherapy, 35.6% experi-
enced induced amenorrhea, and of the 528 women who did not
receive chemotherapy, 5.3% experienced induced amenorrhea
Table 1. Patient Characteristics by Use of Chemotherapy
(BRCA1 and BRCA2 carriers combined)
Characteristic
No
Chemotherapy
(n  528)
Chemotherapy
(n  1,426)
PNo. % No. %
Year of birth  .001
Mean 1948.4 1957.4
Range 1910-1978 1914-1982
Age at diagnosis, years .37
Mean 37.1 37.4
Range 26-47 26-47
BRCA1 .10
Mean 36.7 37.3
Range 26-47 26-47
BRCA2 .35
Mean 38.4 37.9
Range 26-47 26-47
Mutation status .09
BRCA1 391 25.9 1,115 74.0
BRCA2 135 30.9 301 69.0
Country of residence  .001
United States 183 497
Poland 91 382
Canada 148 324
Israel 22 52
Austria 16 50
Italy 18 31
France 13 32
Other 37 58
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(P  .001 for difference). The probability of induced amenorrhea
increased with age at diagnosis (Table 2). Of the carrier patients who
received chemotherapy, the probability of chemotherapy-induced
amenorrheawas 7.2% forwomendiagnosed before age 30 years, 33%
for women diagnosed from age 31 to 44 years, and 79% for women
diagnosed at or after age 45 years (P trend .001). The probability of
chemotherapy-induced amenorrhea was significantly higher for
BRCA2 carriers than for BRCA1 carriers (46.8% v 32.7%; P  .001;
Table 3; Fig 1). The average age at diagnosis of BRCA2 carriers was 1
yearolder than thatofBRCA1 carriers (38v37years); after adjustment
for age at diagnosis, the difference remained significant (P .001). By
age 38 years, 50% of BRCA2 carriers were expected to experience
amenorrhea after chemotherapy, compared with the age of 40 years
expected for BRCA1 carriers. More BRCA2 carriers than BRCA1 car-
riers received tamoxifen (41.4% v 16.1%); therefore, we restricted the
comparison to women who did not receive tamoxifen; in this sub-
group, the probability of chemotherapy-induced amenorrhea was
36.6% for BRCA2 carriers and 27.8% for BRCA1 carriers (P .04).
We also evaluated the impact of tamoxifenuse on theprobability
of inducedamenorrhea forcarrierwomenwhodidanddidnot receive
chemotherapy (Table4).Of518mutationcarrierswhodidnot receive
chemotherapy, those who received tamoxifen had a 5.3% probability
of induced amenorrhea, compared with 5.8% for those who did not
use tamoxifen (P .9; 10 carrier patientsweremissing tamoxifendata
andwere excluded).Of1,403BRCA carrierswhoreceivedchemother-
apy, those who received tamoxifen had a 52% probability of induced
amenorrhea, compared with 29% for those who did not receive ta-
moxifen (P  .001; 33 carrier patients were missing tamoxifen data
and were excluded).
We also evaluated the probability of induced menopause in 167
noncarrier patients with breast cancer who otherwise met the study
criteria. Of the 167 noncarrier patients, 100 women (59%) received
chemotherapy, and of these, 49 (49%) developed chemothera-
py-induced amenorrhea. We compared the age-specific probabilities
of induced amenorrhea among chemotherapy-treatedpatients for the
1,426 mutation carriers and 100 noncarriers (Fig 2). We found no
significant difference between the age-specific probabilities of
chemotherapy-induced amenorrhea for the two groups (P  .18).
Furthermore, therewasnosignificantdifferencewhenBRCA1carriers
were compared with noncarrier controls (P .10) or when BRCA2
carriers were compared with noncarrier controls (P .50). Tamox-
ifenhadbeenadministered to24%of carriers and38%ofnoncarriers.
Table 2. Probability of Induced or Natural Amenorrhea Among
Women Treated With Chemotherapy by Age at Treatment
(BRCA1 and BRCA2 combined)
Age at Treatment
(years)
Induced
Amenorrhea
Natural
Amenorrhea†
TotalNo. % No. %
26 0 0.0 39 100.0 39
27 2 8.0 23 92.0 25
28 2 6.9 27 93.1 29
29 5 11.1 40 88.9 45
30 4 9.3 39 90.7 43
31 3 5.1 56 94.9 59
32 3 4.3 67 95.7 70
33 13 15.1 73 84.9 86
34 15 19.5 62 80.5 77
35 12 14.1 73 85.9 85
36 16 22.2 56 77.8 72
37 15 22.1 53 77.9 68
38 26 29.2 63 70.8 89
39 35 37.6 58 62.4 93
40 40 41.2 57 58.8 97
41 36 59.0 25 41.0 61
42 45 65.2 24 34.8 69
43 44 59.5 30 40.5 74
44 42 76.4 13 23.6 55
45 56 78.9 15 21.1 71
46 42 79.3 11 20.8 53
47 52 78.8 14 21.2 66
Total 508 35.6 918 64.4 1,426
Amenorrhea onset  2 years of breast cancer diagnosis with no resumption
of menses.
†Amenorrhea onset  2 years after breast cancer diagnosis.
Table 3. Probability of Induced Amenorrhea by Chemotherapy and Gene Mutation Status
Chemotherapy
Amenorrhea in BRCA1 Carriers Amenorrhea in BRCA2 Carriers
Amenorrhea in BRCA1 and
BRCA2 Carriers Combined
No. % No. % No. %
No 22 of 391 5.6 6 of 135 4.4 28 of 526 5.3
Yes 364 of 1,115 32.7 141 of 301 46.8 505 of 1,416 35.6
Total 386 of 1,506 25.6 147 of 436 33.7 533 of 1,942 27.4
NOTE. Twelve women had both mutations and were excluded.
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Fig 1. Proportion of patients with induced amenorrhea by age at diagnosis;
BRCA1 versus BRCA2; all patients received chemotherapy.
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Results were similar when women who received tamoxifen were ex-
cluded (data not shown).
Wealsoaddressed thequestionofwhetherwomenwithaBRCA1
or BRCA2 mutation who were treated with chemotherapy and who
experienced return of menses underwent menopause earlier than
women who did not receive chemotherapy. Among all women who
reached age 56 years, the mean age of menopause was 45.4 years for
those who received chemotherapy and resumedmenses and was 49.0
years for those who did not receive chemotherapy (P  .001), a
difference of 3.6 years. Among women who had a BRCA1 mutation
and reached age 56 years, the mean age of menopause was 45.5 years
for thosewhoreceivedchemotherapyand48.7 years for thosewhodid
not receive chemotherapy (P  .001). Among women who had a
BRCA2 mutation and reached age 56 years, the mean age of meno-
pause was 45.2 years for those who received chemotherapy and 49.9
years for those who did not receive chemotherapy (P .003).
DISCUSSION
Chemotherapy can induce transient or permanent amenorrhea. Def-
initions of chemotherapy-induced amenorrhea vary7; we defined it
as 2 years of amenorrhea commencing within 2 years after chemo-
therapywithno resumptionofmenses. Patientswith breast cancer for
whomamenorrhea lasts24monthsafter chemotherapyareunlikely
to resumemenses.7-9
The postmenopausal ovary is characterized by atrophy of the
cortex anddepletion of the follicles.4,6,10 Chemotherapy can target the
oocyte directly (germ cells) or can induce oocyte death indirectly via
damage to somatic cells (granulosa cells).9 Ovarian cytotoxicity is
irreversible; women are born with a fixed number of germ cells, and
these are not replenished.9 Ovarian dysfunction after chemotherapy
depends on patient age and type of chemotherapy received.9,11,12
High-risk agents include alkylating agents; medium-risk agents in-
clude platinum, anthracycline antibiotics, and taxoids; and low-risk
agents include vinca plant alkaloids, some anthracycline antibiotics
such as bleomycin, and antimetabolites such as methotrexate, fluo-
rouracil, andmercaptopurine. In our study, we did not have access to
data regarding specific chemotherapy regimens.
We show here that the probability of chemotherapy-induced
amenorrhea in women who carry a BRCA1 or BRCA2 mutation in-
creases steadily with age at treatment; the probability of induced
amenorrhea was 7% for women age 30 years, 12% for women age
31 to 35 years, and 52% for women age 36 years. It does not seem
that BRCA mutation carriers are at particularly high risk of
chemotherapy-inducedmenopause.The results are similar to thoseof
previous studies that evaluated for sporadic breast cancer cases.13-16
Forty-five percent of women with breast cancer who received CMF
(cyclophosphamide,methotrexate, andfluorouracil) or a similar pro-
tocol experienced amenorrhea 1 year after treatment when age 35 to
40 years, in contrast with 28%of women age 35 years.18 The risk of
amenorrhea resulting from a single-agent or combination regimen
has been estimated to be up to 80% for patients diagnosed at age 40
years, comparedwith 60% if thewoman is age 30 to 39 years and 20%
if the patient is age 30 years at treatment.19,20 Rzepka-Go´rska et al21
found a tendency for premature menopause in BRCA1 mutation
carriers; themean age atmenopause forBRCA1mutation carrierswas
45.5 years, compared with 48.2 years for noncarriers. In this study, 45
of the 81 BRCA1 carriers had breast cancer, and it is difficult to
distinguish if the age of onset of menopause among BRCA1 carriers
was influencedby treatment or byBRCA1 status per se.Wealso found
that among women who had transient amenorrhea after chemother-
apy and then resumed menses, the eventual age of amenorrhea was
advanced, by 3.2 years in BRCA1 carriers and 4.7 years in BRCA2
carriers. A similar effect was reported by Partridge et al22 in patients
with breast cancer from the general public who did and did not
receive chemotherapy.
Oktay et al3 performedovarian stimulation in 126 youngwomen
with breast cancer using letrozole and gonadotropins to cryopreserve
embryos or oocytes. Ovarian reserve was measured by total oocyte
yield and incidence of poor response ( four oocytes retrieved after
ovarian stimulation).They foundahigher fractionofpoor responders
among BRCA1 carriers than noncarriers (four [33.3%] of 12 v one
[3.3%] of 33; P  .014). The sample size of mutation carriers was
small, and it is premature tomake clinical recommendations basedon
this article. We found a statistically significantly higher proportion of
women experiencing amenorrhea if they had aBRCA2 versusBRCA1
mutation,but forneither subgroupwas theprobabilityof amenorrhea
higher than that of the noncarrier population. There is no clear bio-
logic rationale for why a BRCA1 germlinemutation should be associ-
ated with early menopause; Oktay et al propose that because DNA
Table 4. Probability of Induced Amenorrhea by Chemotherapy
and Tamoxifen Use
Treatments Received
Induced
Amenorrhea
Natural
Amenorrhea
TotalNo. % No. %
No chemotherapy; no
tamoxifen 24 5.3 426 94.6 450
No chemotherapy;
tamoxifen 4 5.8 64 94.1 68
Chemotherapy; no
tamoxifen 288 29.0 705 71.0 993
Chemotherapy; tamoxifen 214 52.2 196 47.8 410
Total 536 1,418 1,954
NOTE. Information on tamoxifen was missing for 33 patients.
Pr
op
or
tio
n 
W
ith
 In
du
ce
d
Am
en
or
rh
ea
Age at Breast Cancer Diagnosis (years)
1.0
0.8
0.6
0.4
0.2
0
26 28 30 32 34 36 38 40 42 44 46
P = .28
Noncarrier (n = 100)
Carrier (n = 1,426)
Fig 2. Proportion of patients with induced amenorrhea by age at diagnosis;
mutation carriers versus noncarriers; all patients received chemotherapy.
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repair is deficient in patients with BRCAmutations, oocytes might be
more prone to DNA damage.
We also evaluated the impact of tamoxifen on amenorrhea. In
the absence of chemotherapy, therewas no association betweenuse of
tamoxifen and onset of long-term amenorrhea, but tamoxifen aug-
mented the toxicity of chemotherapy. Several other results support
our findings.13,22 In the NSABP (National Surgical Adjuvant Breast
and Bowel Project) B-30 trial23 708 premenopausal patients were
treatedwith anthracyclines and docetaxel. The rate of chemotherapy-
induced amenorrhea was strongly influenced by the addition of ta-
moxifen (29% v 52%;P .003). Perez-Fidalgo et al13 reported that in
younger patients, tamoxifen contributes to the delayed recovery of
menses. Jung et al24 reviewed 241 premenopausal patients with breast
cancer who underwent adjuvant CMF or flourouracil, doxorubicin,
andcyclophosphamide therapyand found that theadditionof tamox-
ifen to chemotherapy increased the incidence of chemothera-
py-inducedamenorrhea from48%to64%(P .02). Fornier et al25 in
a cohort of women with breast cancer age  40 years found the
incidence of chemotherapy-induced amenorrhea to be 13% for pa-
tients treated only with chemotherapy and 17% for patients treated
with chemotherapy and tamoxifen. The mechanism is unclear; how-
ever, tamoxifen increases circulating estrogen, which may induce a
negative feedback of the hypothalamic-ovarian axis.25 The opposite
effect has been noted in several patients treated with an aromatase
inhibitor. Aromatase inhibitors lead to an increase in the secretion of
pituitary gonadotrophins, andwhenused as adjuvant hormonal ther-
apy, they can sometimes induce a resumption ofmenses. Smith et al26
found that of 45womenwith breast cancer age 39 to 52 yearswhohad
ceased menses after chemotherapy, 12 women (27%) had a resump-
tion of ovarian function after starting an aromatase inhibitor.
Several strategies have been used to preserve fertility in cancer
survivors who receive chemotherapy, including embryo and
oocyte cryopreservation.12 Gonadotropin-releasing hormone
(GnRH) has been used to suppress the ovaries during chemother-
apy to protect the pool of follicles.11 The SWOG (Southwest On-
cologyGroup) 0230 randomized clinical trial will evaluate the rates
of ovarian failure with and without GnRH in premenopausal
women with hormone receptor–negative breast cancer. In the
United Kingdom, OPTION (Ovarian Protection Trial in Pre-
menopausal Breast Cancer Patients) is also assessing the impact of
chemotherapy and the protective effect of GnRH on ovarian func-
tion at 12 months after breast cancer treatment.12,29,30
Young age at menopause has been linked to several adverse
health outcomes, including osteoporosis,31cardiovascular disease,32
and overall mortality.33 Finch et al34 reported that in the short term
after surgically inducedmenopause,qualityof life seemedtobe similar
before and after oophorectomy in BRCA1 and BRCA2 carriers; how-
ever, vasomotor symptoms and declines in sexual functioning were
common.Hormone replacement therapy is not recommended after a
diagnosis of breast cancer, leaving limited options for the manage-
ment ofmenopause in this groupof patients.Wehave recently shown
that oophorectomy is associated with improved survival in BRCA1
carriers treated for early-onset breast cancer.35 It is important to estab-
lish whether the preservation of ovarian function in young women
with breast cancer and a BRCA mutation has an adverse impact on
disease recurrence.
In conclusion, BRCA mutation carriers age  35 years who
receive chemotherapy for breast cancer are at high risk of develop-
ing long-term amenorrhea, but the probability of induced amen-
orrhea does not seem to be greater than that in the noncarrier
population, and BRCA1 or BRCA2 status per se should not be an
indication for referral to a fertility clinic. If tamoxifen is added to
chemotherapy, the risk of amenorrhea is much higher. Women
with breast cancer whowish to preserve fertility should be aware of
the synergistic impact of chemotherapy and tamoxifen on induc-
ing long-term amenorrhea and possibly menopause. Future stud-
ies should evaluate the impact of induced amenorrhea and ovarian
preservation on survival inwomenwith breast cancer and aBRCA1
or BRCA2mutation.
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